Chinese guidelines prioritize the use of Azvudine and nirmatrelvir–ritonavir in COVID‐19
patients. Nevertheless, the real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir …

Paxlovid associated with decreased hospitalization rate among adults with COVID-19 —
United States, April–September 2022 - American Journal of Transplantation Skip to Main …

Background Real-world data is currently limited on the association between oral antiviral
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …

Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …

On Dec 22, 2021, the US Food and Drug Administration (FDA) issued an emergency use
authorisation for Pfizer's COVID-19 antiviral, Paxlovid. Trial results released by the …

Background: A randomized controlled trial involving a high-risk, unvaccinated population
that was conducted before the Omicron variant emerged found that nirmatrelvir–ritonavir …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …

Coronavirus disease 2019 (COVID‐19) is a continued leading cause of hospitalization and
death. Safe, efficacious COVID‐19 antivirals are needed urgently. Nirmatrelvir (PF …

Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir
and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials …

Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …